AXYNTIS

What AXYNTIS does

AXYNTIS is a French independent fine chemistry CDMO founded in 2007 and headquartered in Paris, operating as the largest independent multi-site fine chemistry group in France with 6 manufacturing sites and 3 R&D centers across the country. The company is organized into specialized subsidiaries: Orgapharm (Pithiviers, advanced intermediates and APIs with chromatography and HPAPI capabilities), Centipharm (Grasse, generic APIs with DMF/CEP regulatory dossiers), Kyrapharm (preparative chromatography), Steiner (Saint-Marcel, dyes for paper and petroleum industries), and Synthexim (Calais, acquired from Calaire Chimie in 2013). Its technology stack spans fine chemistry synthesis from laboratory (Kilolab) to industrial GMP-compliant scale, with specialized capabilities in preparative chromatography, hydrogenation, HPAPI synthesis, and emerging bioproduction (MIAMI project for microbial cell factory-based alkaloid production, developed with Université de Tours and John Innes Center).

The company operates a B2B contract manufacturing model serving pharmaceutical companies (custom API synthesis, generic APIs, HPAPIs for anticancer drugs, clinical lot manufacturing — ~50% of revenue), cosmetics and fragrance firms (specialty chemical intermediates), and industrial colorant buyers (paper and petroleum sectors via the Steiner division). Revenue is project-specific and quote-based under CDMO contracts, with over 70% of revenue generated from international exports. Key customers include Innova Medical Group (COVID-19 rapid antigen test production at 5 million units/month capacity) and Provepharm Life Solutions (Proveblue/methylene blue production at Pithiviers). The company is strategically positioned within French pharmaceutical sovereignty initiatives, having secured two France Relance awards in 2021 (8M€ investment, 3.6M€ from BPI/PIA, projecting 16M€ incremental annual revenue) for HPAPI manufacturing and API reshoring. Founder David Simonnet controls the capital, with Japanese partner Fuji Silysia holding an equity stake, and no public listing or institutional PE/VC backing is disclosed.

Name

AXYNTIS

Legal name

Axyntis Group

Website

https://axyntis.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

251–500 employees

Short description

AXYNTIS is a French independent fine chemistry CDMO operating 6 manufacturing sites, providing GMP-compliant custom API synthesis, generic APIs, HPAPIs, and chromatography services primarily to pharmaceutical and cosmetic clients, with over 70% of revenue exported internationally.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Manufacturing

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Medicinal and Botanical Manufacturing (325411), Pharmaceutical Preparation Manufacturing (325412)

SIC

Medicinal Chemicals & Botanical Products (2833), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Small-Molecule API & Intermediates CDMO (HLAGABAA)

akta.pro secondary industries

Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)

Keywords

• Contract manufacturing
• Fine chemicals
• Active pharmaceutical ingredients
• Custom synthesis
• GMP manufacturing

Headquarters

HQ city

Paris

HQ country

France

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Infrastructure, Supply Chain, Technology or R&D, Marketing or Sales

Revenue model

1. CDMO Contract Manufacturing Services: As a CDMO (Contract Development and Manufacturing Organization), AXYNTIS earns revenue through contract manufacturing services for pharmaceutical and cosmetic companies, developing and producing custom molecules and APIs under GMP conditions for third-party clients. This represents the majority of revenue.
2. Product Sales (Intermediates, APIs, Specialty Chemicals):

Go-to-market motion2 records

Distribution channels1 record

Marketing channels7 records

Core offering

AXYNTIS is a French independent fine chemistry group operating as a Contract Development and Manufacturing Organization (CDMO). The company manufactures active pharmaceutical ingredients (APIs), advanced intermediates, generic APIs, high-potency APIs (HPAPIs), specialty chemicals, and industrial dyes/colorants across six manufacturing sites in France, serving pharmaceutical, cosmetic, and industrial customers.

Differentiator

Problem solved

Functional benefit

Brands

• Orgapharm: Subsidiary specializing in advanced intermediates and active pharmaceutical ingredients production, plus chromatography services
• Centipharm
• Steiner
• Kyrapharm
• Synthexim

Products and services

• CDMO Contract Manufacturing Services Contract development and manufacturing organization services spanning the full lifecycle from R&D and process development through pilot and industrial-scale production for pharmaceutical and fine chemical clients.
• Active Pharmaceutical Ingredients (APIs) Custom and catalog production of active pharmaceutical ingredients for originator and generic drug manufacturers.
• High-Potency API (HPAPI) Manufacturing Specialized manufacturing of high-potency active pharmaceutical ingredients under contained conditions for oncology and other sensitive therapeutic applications.
• Generic APIs Production of generic active pharmaceutical ingredients accompanied by Drug Master Files (DMF) and Certificates of Suitability (CEP) for regulatory submissions.
• Preparative Chromatography Services Custom purification services using preparative chromatography techniques, scaling from lab to industrial batch sizes for pharmaceutical and fine chemical applications.
• Industrial Dyes and Colorants Production of specialty dyes and colorants for industrial applications including paper manufacturing, petroleum, ink, textile, and detergent sectors.
• Hydrogenation Services Industrial hydrogenation reactions and custom synthesis services used in the production of pharmaceutical intermediates and APIs.
• Advanced Chemical Intermediates Manufacture of advanced chemical intermediates used as building blocks in pharmaceutical synthesis and fine chemistry.
• Natural Vindoline Production Biosynthetic production of natural vindoline, a vinca alkaloid intermediate used as a precursor in anti-cancer drug synthesis.
• Specialty Cosmetic Ingredients Manufacture of specialty chemical ingredients such as dimethyl sulfone, methylsulfonylmethane, and antioxidant actives for the cosmetics and personal care industry.

Quantifiable outcome

• 5 million COVID-19 antigen tests produced per month at Pithiviers for Innova Medical Group
• +3 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Six partnerships are on record, tiered core.

• Innova Medical GroupcoreStrategic or Co-development Partner · 29 October 2021Axyntis produces rapid COVID-19 antigen detection tests for California-based Innova Medical Group at its Pithiviers site (Orgapharm). The partnership reached capacity of 5 million tests/month, described as a long-term implantation by both parties. Axyntis as manufacturer/producer for IMG's products.
• MIAMI Project ConsortiumcoreStrategic or Co-development Partner · 23 May 2019Axyntis is a partner in the MIAMI (Monoterpenoid Alkaloids in Microbial cell factories) project, a research initiative developing tools and methodologies to discover complex plant biosynthetic pathways and optimize production in microbes. This represents Axyntis's strategic entry into bioproduction.
• Provepharm Life SolutionscoreStrategic or Co-development Partner · 9 October 2017Axyntis signed a new agreement with Provepharm Life Solutions for the production of Proveblue (methylene blue pharmaceutical product) on the Pithiviers platform. Dedicated investment to increase production capacity, particularly for European and American markets.
• Nippon Chemicals (Japan)coreStrategic or Co-development Partner · 1 October 2017Strategic partnership signed during CPhI with Nippon Chemicals (a listed Japanese group) to develop phosphorated ligand chemistry within Axyntis's production facilities. This represents a technology development partnership in a specialized chemistry domain.
• Université de Tours / John Innes CentercoreStrategic or Co-development Partner · 1 January 2017Collaboration with the Biomolecules et Biotechnologies Végétales (BBV) laboratory at Université de Tours and the John Innes Center (Norwich, UK) for the development of natural vindoline production through microbial cell factories, enabling anticancer drug development independent of Madagascar periwinkle plant supply.
• Fuji Silysia (Japan)coreStrategic or Co-development Partner · 1 January 2015Strategic alliance with Japanese group Fuji Silysia, which holds a stake alongside founder David Simonnet. The partnership includes joint R&D (construction of a dedicated silica grafted R&D laboratory for chromatography applications) and is described as a long-term strategic alliance supporting Axyntis's chromatography and specialty silica activities.

Scale indicators9 records

Recent moves10 records

Expansion highlights7 records

Direct peers

• Novasep: French CDMO specializing in active pharmaceutical ingredients, HPAPIs, and chromatography-based purification — closely matches Axyntis's HPAPI and preparative chromatography capabilities, both with European manufacturing footprints.
• Fareva: Major French CDMO/CMO serving pharmaceutical and cosmetic industries with custom synthesis and formulation — overlapping customer base (pharma + cosmetics) and similar European manufacturing footprint to Axyntis.
• Minakem: French specialty CDMO focused on complex API synthesis, HPAPIs, and high-containment manufacturing — directly comparable in scale, French base, and HPAPI specialization to Axyntis's Pithiviers platform.
• Seqens: French-headquartered global CDMO and API manufacturer offering custom synthesis, generics, and specialty ingredients across pharmaceutical, cosmetic, and industrial end markets — directly comparable to Axyntis's fine chemistry CDMO model and customer base.
• PCAS (now part of Seqens group): French fine chemicals and API manufacturer historically grouped with Axyntis and Sanofi Chimie in the 'top 3' French third-party API producers — directly comparable in custom synthesis, generic APIs, and pharmaceutical intermediates.

Broad incumbents

• Catalent: Global CDMO serving pharmaceutical and consumer health with custom API and drug product development — comparable CDMO business model though at much larger scale and broader service offering than Axyntis.
• Lonza: Swiss-headquartered global CDMO leader in API and biologics manufacturing — comparable in HPAPI and custom synthesis capabilities, though at a vastly larger scale spanning many more therapeutic areas.
• Sanofi Chimie: Captive fine chemicals/API arm of Sanofi historically cited alongside Axyntis in France's top-3 third-party API producers — operates at much larger scale as an integrated pharma manufacturer, but comparable in chemistry capability and French footprint.

Emerging players

• Cambrex: Mid-sized CDMO specializing in small-molecule APIs, controlled substances, and HPAPIs — directly comparable in scale, custom synthesis focus, and HPAPI capability, though US-headquartered rather than European.
• WuXi STA (WuXi AppTec): Asia-based global CDMO with extensive small-molecule API and intermediate manufacturing capacity — competing with Axyntis in the same CDMO space, particularly for European pharma customers seeking offshore API production.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat7 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/axyntis
• YouTubeyoutube.com/channel/UC6pw5K-yuo4o3s6tPJU7sdg
• Facebookfacebook.com/sharer.php?u=https%3A%2F%2Fwww.axyntis.com%2Ffr%2Factualites-axyntis

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AXYNTIS